Spectrum Pharma (SPPI) Tops Q2 EPS by 24c

Spectrum Pharma (NASDAQ: SPPI) reported Q2 EPS of ($0.05), $0.24 better than the analyst estimate of ($0.29). Revenue for the quarter came in at $30.9 million versus the consensus estimate of $30.88 million.

Non-GAAP net loss was $0.5 million, or $(0.01) per basic and diluted share in the comparable period in 2015.

For earnings history and earnings-related data on Spectrum Pharma (SPPI) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• JPMorgan Downgrades JD Logistics Inc (2618:HK) (JDLGF) to Neutral
• Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15